Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population.

Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population.
复制标题

日本人群中肌痛性脑脊髓炎/慢性疲劳综合征的深层表型

DOI:
10.1038/s41598-020-77105-y
复制
发表时间:
2020-11-16
期刊:
影响因子:
4.6
通讯作者:
Watanabe Y
Watanabe Y
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Kitami T;Fukuda S;Kato T;Yamaguti K;Nakatomi Y;Yamano E;Kataoka Y;Mizuno K;Tsuboi Y;Kogo Y;Suzuki H;Itoh M;Morioka MS;Kawaji H;Koseki H;Kikuchi J;Hayashizaki Y;Ohno H;Kuratsune H;Watanabe Y

文献摘要

被引文献

相似文献

肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)是一种复杂且使人衰弱的疾病,没有分子诊断和治疗选择。为了确定这种疾病的潜在标志物,我们对48名患者和52名对照进行了标准实验室测试、血浆代谢组学、血液免疫表型和转录组学以及粪便微生物组分析。在这里,我们确定了一组26个潜在的分子标记,将ME/CFS患者与健康对照区分开来。单核细胞数量、微生物群丰度和脂蛋白谱似乎是最有信息的标记。当我们将这些分子变化与睡眠和疲劳的认知测量相关联时,我们发现脂蛋白和微生物组谱与睡眠中断最密切相关,而另一组标记与认知参数相关。睡眠、脂蛋白和微生物组的变化发生在疾病过程的早期,这表明这些标志物可以在更大的队列中进行检测,以获得潜在的生物标志物应用。我们的研究指出,在我们的日本队列中,与睡眠相关的一系列分子变化是ME/CFS的一个突出特征。
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex and debilitating disease with no molecular diagnostics and no treatment options. To identify potential markers of this illness, we profiled 48 patients and 52 controls for standard laboratory tests, plasma metabolomics, blood immuno-phenotyping and transcriptomics, and fecal microbiome analysis. Here, we identified a set of 26 potential molecular markers that distinguished ME/CFS patients from healthy controls. Monocyte number, microbiome abundance, and lipoprotein profiles appeared to be the most informative markers. When we correlated these molecular changes to sleep and cognitive measurements of fatigue, we found that lipoprotein and microbiome profiles most closely correlated with sleep disruption while a different set of markers correlated with a cognitive parameter. Sleep, lipoprotein, and microbiome changes occur early during the course of illness suggesting that these markers can be examined in a larger cohort for potential biomarker application. Our study points to a cluster of sleep-related molecular changes as a prominent feature of ME/CFS in our Japanese cohort.